Case ReportRadiation Therapy and Sorafenib: Clinical Data and Rationale for the Combination in Metastatic Renal Cell Carcinoma
References (6)
- et al.
Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model
J Urol
(1997) - et al.
Randomized phase III trial of Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell cancer
J Clin Oncol
(2005) - et al.
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
J Clin Oncol
(2006)
Cited by (32)
The role of macrophage phenotype in regulating the response to radiation therapy
2018, Translational ResearchCitation Excerpt :In a murine model of pancreatic cancer, sunitinib sensitized pancreatic tumors, making them more susceptible to RT.160 In a phase 2 trial of patients with localized high-risk prostate cancer, prolonged disease control was observed with the combined application of sunitinib, chemotherapy, and RT.161 Pathologic analysis of the tissue suggested that the combination of RT, chemotherapy, and a similar tyrosine kinase inhibitor, sorafenib, can reverse TAMs to an antitumor phenotype.162 Similar enhanced efficacy was seen in metastatic renal cell carcinoma162 and unresectable hepatocellular carcinoma.163 In summary, although these agents all undoubtedly have effects outside of their impact on myeloid-macrophage cells, some of their bioactivity is likely attributable to their ability to influence the functional phenotype of macrophages.
Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer
2012, Urologic Oncology: Seminars and Original InvestigationsSorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo
2012, Biomedicine and PharmacotherapyCurrent state of knowledge regarding the use of antiangiogenic agents with radiation therapy
2011, Cancer Treatment Reviews
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1558-7673, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.